Efgartigimod Alfa + Placebo

Phase 2Recruiting

1 views this week 0 watching💤 Quiet

Interest: 39/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Optic Neuritis

Conditions

Optic Neuritis

Trial Timeline

Aug 12, 2025 → Jul 1, 2027

NCT ID

NCT06453694

About Efgartigimod Alfa + Placebo

Efgartigimod Alfa + Placebo is a phase 2 stage product being developed by Argenx for Optic Neuritis. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06453694. Target conditions include Optic Neuritis.

What happened to similar drugs?

4 of 14 similar drugs in Optic Neuritis were approved

Approved (4) Terminated (4) Active (8)

✅Satralizumab 120 mgChugai PharmaceuticalApproved

✅InebilizumabAmgenApproved

✅Diagnostic proceduresBayerApproved

✅IdebenoneSanthera PharmaceuticalsApproved

🔄Satralizumab + Placebo + Baseline TreatmentChugai PharmaceuticalPhase 3

🔄Satralizumab + PlaceboChugai PharmaceuticalPhase 3

🔄satralizumab + azathioprine (AZA) + mycophenolate mofetil (MMF) + oral corticosteroidsRochePhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06453694	Phase 2	Recruiting	Aug 12, 2025	Jul 1, 2027	Optic Neuritis

Competing Products

20 competing products in Optic Neuritis

See all competitors

Product	Company	Stage	Hype Score
Satralizumab 120 mg	Chugai Pharmaceutical	Approved	35
Satralizumab + Placebo + Baseline Treatment	Chugai Pharmaceutical	Phase 3	40
Satralizumab + Placebo	Chugai Pharmaceutical	Phase 3	40
PDE5 Inhibitors	Eli Lilly	Pre-clinical	26
Atacicept + Placebo matched to atacicept	Merck	Phase 2	27
Fingolimod 0.5mg/daily + Placebo	Novartis	Phase 2	27
satralizumab + azathioprine (AZA) + mycophenolate mofetil (MMF) + oral corticosteroids	Roche	Phase 3	40
Satralizumab	Roche	Phase 3	47
UPLIZNA	Amgen	Pre-clinical	33
Inebilizumab	Amgen	Phase 2	42
Inebilizumab	Amgen	Approved	47
Zyvox - linezolid + Matched control	Pfizer	Phase 3	32
Dexmedetomidine HCL Injection + Placebo	Pfizer	Phase 3	40
No intervention	Pfizer	Pre-clinical	26
Diagnostic procedures	Bayer	Approved	32
Placebo + BIIB033 100mg/Kg	Biogen	Phase 2	32
BIIB033 (anti-LINGO-1 mAb) + Placebo	Biogen	Phase 2	32
intravenous methylprednisolone	Brain Biotech	Pre-clinical	23
OCS-05 +SoC (corticosteroid) IV administration	Oculis Holding AG	Phase 2	29
EVO756 + EVO756 + EVO756 + Placebo control	Evommune	Phase 2	36